U.S. FDA compliance issues at Pithampur and Monroe plants
Pithampur plant under FDA discussion; Monroe plant awaiting inspection. Delays could impact U.S. launch timelines.
GLENMARK / Q4-FY25 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Diabetes portfolio erosion in India
Remogliflozin and Teneligliptin, which contributed ~60% of diabetes sales, faced generic competition; new launches (Lirafit, Empagliflozin) yet to fully offset decline.
Delayed U.S. launches and lack of meaningful approvals
North America revenue declined 5.4% due to back-ended launches; Flovent and nasal spray approvals may slip further.
IGI licensing deal uncertainty
ISB 2001 licensing deal is critical to fund IGI's $70M annual burn; any delay could pressure margins.